Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial.

•The sequence of sorafenib and regorafenib for patients with hepatocellular carcinoma was evaluated.•Median survivals from the start of sorafenib were 26 months (regorafenib) and 19 months (placebo).•Regorafenib conferred benefit regardless of time to progression on prior sorafenib.•Regorafenib tolerability was comparable regardless of the last sorafenib dose.